يعرض 1 - 10 نتائج من 463 نتيجة بحث عن '"Chiarion Sileni, V"', وقت الاستعلام: 1.61s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

    المؤلفون: Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M

    المصدر: Cancer Management and Research, Vol Volume 15, Pp 1271-1281 (2023)

    مصطلحات موضوعية: braf mutation, dabrafenib, melanoma, real-world, trametinib, managed access program, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    العلاقة: https://www.dovepress.com/characteristics-of-real-world-patients-with-high-risk-brafv600ek-mutat-peer-reviewed-fulltext-article-CMARTest; https://doaj.org/toc/1179-1322Test

    الوصول الحر: https://doaj.org/article/61e573f959ce4c9193d56a436410e730Test

    View record in DOAJ النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    المؤلفون: Ascierto, PA, Mandalà, M, Ferrucci, PF, Guidoboni, M, Rutkowski, P, Ferraresi, V, Arance, A, Guida, M, Maiello, E, Gogas, H, Richtig, E, Fierro, MT, Lebbè, C, Helgadottir, H, Queirolo, P, Spagnolo, F, Tucci, M, Del Vecchio, M, Gonzales Cao, M, Minisini, AM, De Placido, S, Sanmamed, MF, Mallardo, D, Curvietto, M, Melero, I, Palmieri, G, Grimaldi, AM, Giannarelli, D, Dummer, R, Chiarion Sileni, V

    المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(2):212-221

    مصطلحات موضوعية: Medicin och hälsovetenskap

    الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:236049147Test


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Real‐world multicentre observational study of effectiveness and toxicity in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab

    المؤلفون: Faoro, L., Salizzato, V., Coppola, M., Carpanese, D., Fabozzi, A., Tondulli, L., Marconcini, R., Spagnolo, F., Del Bianco, P., Chiarion‐Sileni, V., Piccin, L.

    المساهمون: Istituto Oncologico Veneto

    المصدر: Journal of the European Academy of Dermatology and Venereology ; ISSN 0926-9959 1468-3083

    الإتاحة: https://doi.org/10.1111/jdv.20066Test

    View record in BASE

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

    المؤلفون: Long, GV, Flaherty, KT, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandala, M, Millward, M, Arance, A, Bondarenko, I, Haanen, JBAG, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, MA, Lane, SR, Legos, JJ, Mookerjee, B, Grob, JJ

    المصدر: Annals of oncology : official journal of the European Society for Medical Oncology. 28(7):1631-1639

    مصطلحات موضوعية: Medicin och hälsovetenskap

    الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:136052661Test

    View record in SwePub النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

    المؤلفون: Ascierto PA, Cioli E, Chiarion-Sileni V, Quaglino P, Spagnolo F, Guidoboni M, Del Vecchio M, Peris K, Queirolo P, Fioretto L, Caracò C, Paone M, Sorrentino A, Capone M, Giannarelli D, Ferrara G, Massi D, Trojaniello C.

    المساهمون: Ascierto, Pa, Cioli, E, Chiarion-Sileni, V, Quaglino, P, Spagnolo, F, Guidoboni, M, Del Vecchio, M, Peris, K, Queirolo, P, Fioretto, L, Caracò, C, Paone, M, Sorrentino, A, Capone, M, Giannarelli, D, Ferrara, G, Massi, D, Trojaniello, C.

    مصطلحات موضوعية: metastatic melanoma, cobimetinib, vemurafenib, atezolizumab, neoadjuvant therapy

    وصف الملف: STAMPA

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36845751; info:eu-repo/semantics/altIdentifier/wos/WOS:000944656400001; volume:13; firstpage:1107307-1; lastpage:1107307-8; numberofpages:8; journal:FRONTIERS IN ONCOLOGY; https://hdl.handle.net/11392/2530089Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85148909857; https://www.frontiersin.org/articles/10.3389/fonc.2023.1107307/fullTest

    الإتاحة: https://doi.org/10.3389/fonc.2023.1107307Test
    https://hdl.handle.net/11392/2530089Test

    View record in BASE

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.

    المؤلفون: Larkin, J, Del Vecchio, M, Mandala, M, Gogas, H, Arance, AM, Dalle, S, Cowey, CL, Schenker, M, Grob, J-J, Chiarion-Sileni, V, Marquez-Rodas, I, Butler, MO, Di Giacomo, AM, Middleton, MR, Lutzky, J, de la Cruz-Merino, L, Arenberger, P, Atkinson, V, Hill, AG, Fecher, LA, Millward, M, Nathan, PD, Khushalani, NI, Queirolo, P, Ritchings, C, Lobo, M, Askelson, M, Tang, H, Dolfi, S, Ascierto, PA, Weber, J

    المساهمون: Larkin, James

    جغرافية الموضوع: United States

    وصف الملف: Print-Electronic; CCR-22-3145 -; application/pdf

    العلاقة: 725906; Clinical Cancer Research, 2023, pp. CCR-22-3145 -; https://repository.icr.ac.uk/handle/internal/5881Test

    الإتاحة: https://doi.org/10.1158/1078-0432.CCR-22-3145Test
    https://repository.icr.ac.uk/handle/internal/5881Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.

    المؤلفون: Ascierto, PA, Lipson, EJ, Dummer, R, Larkin, J, Long, GV, Sanborn, RE, Chiarion-Sileni, V, Dréno, B, Dalle, S, Schadendorf, D, Callahan, MK, Nyakas, M, Atkinson, V, Gomez-Roca, CA, Yamazaki, N, Tawbi, HA, Sarkis, N, Warad, D, Dolfi, S, Mitra, P, Suryawanshi, S, Grob, J-J

    المساهمون: Larkin, James

    جغرافية الموضوع: United States

    وصف الملف: Print-Electronic; application/pdf

    العلاقة: Journal of Clinical Oncology, 2023, pp. JCO2202072 -; https://repository.icr.ac.uk/handle/internal/5779Test

    الإتاحة: https://doi.org/10.1200/JCO.22.02072Test
    https://repository.icr.ac.uk/handle/internal/5779Test

    View record in BASE

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

    المؤلفون: Guida M., Bartolomeo N., Quaresmini D., Quaglino P., Madonna G., Pigozzo J., Di Giacomo A. M., Minisini A. M., Tucci M., Spagnolo F., Occelli M., Ridolfi L., Queirolo P., De Risi I., Valente M., Sciacovelli A. M., Chiarion Sileni V., Ascierto P. A., Stigliano L., Strippoli S.

    المساهمون: Guida, M., Bartolomeo, N., Quaresmini, D., Quaglino, P., Madonna, G., Pigozzo, J., Di Giacomo, A. M., Minisini, A. M., Tucci, M., Spagnolo, F., Occelli, M., Ridolfi, L., Queirolo, P., De Risi, I., Valente, M., Sciacovelli, A. M., Chiarion Sileni, V., Ascierto, P. A., Stigliano, L., Strippoli, S.

    مصطلحات موضوعية: Checkpoint inhibitor, Metastatic melanoma, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, Blood Platelet, Human, Immunotherapy, Lymphocyte, Prognosi, Prospective Studie, Proto-Oncogene Proteins B-raf, Retrospective Studie, Melanoma, Neutrophils

    وصف الملف: ELETTRONICO

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35382857; info:eu-repo/semantics/altIdentifier/wos/WOS:000778499200004; volume:20; issue:1; firstpage:1; lastpage:15; numberofpages:15; journal:JOURNAL OF TRANSLATIONAL MEDICINE; https://hdl.handle.net/11365/1221041Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85127719534; https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03359-xTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981693Test/

    الإتاحة: https://doi.org/10.1186/s12967-022-03359-xTest
    https://hdl.handle.net/11365/1221041Test
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981693Test/

    View record in BASE

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

    المؤلفون: Larkin J., Weber J., Del Vecchio M., Gogas H., Arance A. M., Dalle S., Cowey C. L., Schenker M., Grob J. -J., Chiarion-Sileni V., Marquez-Rodas I., Butler M. O., Di Giacomo A. M., Middleton M. R., De la Cruz-Merino L., Arenberger P., Atkinson V., Hill A., Fecher L. A., Millward M., Khushalani N. I., Queirolo P., Long G. V., Lobo M., Askelson M., Ascierto P. A., Mandala M.

    المساهمون: Larkin, J., Weber, J., Del Vecchio, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J. -J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Middleton, M. R., De la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A., Fecher, L. A., Millward, M., Khushalani, N. I., Queirolo, P., Long, G. V., Lobo, M., Askelson, M., Ascierto, P. A., Mandala, M.

    مصطلحات موضوعية: AJCC-8 criteria, Distant metastase, Ipilimumab, Melanoma adjuvant therapy, Nivolumab, Recurrence-free survival, Stage 3, Adjuvants, Immunologic, Human, Neoplasm Staging, Melanoma, Skin Neoplasms

    وصف الملف: STAMPA

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35964471; info:eu-repo/semantics/altIdentifier/wos/WOS:000922633300002; volume:173; firstpage:285; lastpage:296; numberofpages:12; journal:EUROPEAN JOURNAL OF CANCER; https://hdl.handle.net/11365/1221042Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85135858543; https://www.sciencedirect.com/science/article/pii/S0959804922003926Test

    الإتاحة: https://doi.org/10.1016/j.ejca.2022.06.041Test
    https://hdl.handle.net/11365/1221042Test
    https://www.sciencedirect.com/science/article/pii/S0959804922003926Test

    View record in BASE

    أضف إلى المفضلة
  10. 10
    مؤتمر
    First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted Therapy study)

    المؤلفون: Ascierto PA, Mandalà M, Ferrucci PF, Rutkowski P, Guidoboni M, Arance Fernandez AM, Ferraresi V, Maiello E, Guida M, Del Vecchio M, Fierro MT, Queirolo P, Lebbè C, Helgadottir H, Melero I, Palmieri G, Giannarelli D, Grimaldi AM, Dummer R, Chiarion-Sileni V

    المساهمون: Ascierto, Pa, Mandalà, M, Ferrucci, Pf, Rutkowski, P, Guidoboni, M, Arance Fernandez, Am, Ferraresi, V, Maiello, E, Guida, M, Del Vecchio, M, Fierro, Mt, Queirolo, P, Lebbè, C, Helgadottir, H, Melero, I, Palmieri, G, Giannarelli, D, Grimaldi, Am, Dummer, R, Chiarion-Sileni, V

    وصف الملف: STAMPA

    العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000573469102673; ispartofbook:Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020; ESMO Virtual Congress2020; volume:31; issue:S4; firstpage:S1173; lastpage:S1174; numberofpages:2; journal:ANNALS OF ONCOLOGY; https://hdl.handle.net/11392/2530081Test; https://www.sciencedirect.com/science/article/pii/S0923753420423579Test

    الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.2275Test
    https://hdl.handle.net/11392/2530081Test
    https://www.sciencedirect.com/science/article/pii/S0923753420423579Test

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث